A phase II trial of paclitaxel and carboplatin in the treatment of hormone-refractory prostate cancer (HRPC).
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2012
At a glance
- Drugs Carboplatin; Paclitaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Mar 2012 Actual patient numbers amended from 83 to 58 as reported by ClinicalTrials.gov.
- 09 Feb 2012 Bristol-Myers Squibb trial company and lead trial centre added as reported by ClinicalTrials.gov.